Home / Business and Economy / Novartis CEO Confirms No Exit Plans Amid Growth Phase
Novartis CEO Confirms No Exit Plans Amid Growth Phase
21 Jul
Summary
- CEO Vas Narasimhan will guide Novartis through its next growth phase.
- The company anticipates significant drug trial data later this year.
- Novartis is navigating patent expirations for key drugs like Entresto.
Novartis CEO Vas Narasimhan has affirmed his commitment to leading the Swiss pharmaceutical giant through its next expansionary period. This confirmation comes as the company prepares to release pivotal drug trial data in the latter half of the year.
Narasimhan stated on Tuesday that his plans remain unchanged, expressing anticipation for the upcoming trial results and the subsequent drug launches planned for the following year. He also highlighted the ongoing strategic focus on transforming the company through artificial intelligence.
Since assuming the CEO role in 2018, Narasimhan has been steering Novartis through a challenging phase marked by the expiration of patents for several of its significant medications. This includes the blockbuster heart failure drug, Entresto, underscoring the company's need for strategic growth and new product development.
